Center of Excellence in Environmental Toxicology, Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6084, USA.
J Steroid Biochem Mol Biol. 2011 May;125(1-2):46-56. doi: 10.1016/j.jsbmb.2011.01.009. Epub 2011 Jan 25.
Hydroxysteroid dehydrogenases (HSDs) represent a major class of NAD(P)(H) dependent steroid hormone oxidoreductases involved in the pre-receptor regulation of hormone action. This is achieved by HSDs working in pairs so that they can interconvert ketosteroids with hydroxysteroids resulting in a change in ligand potency for nuclear receptors. HSDs belong to two protein superfamilies the aldo-keto reductases and the short-chain dehydrogenase/reductases. In humans, many of the important enzymes have been thoroughly characterized including the elucidation of their three-dimensional structures. Because these enzymes play fundamental roles in steroid hormone action they can be considered to be drug targets for a variety of steroid driven diseases, e.g. metabolic syndrome and obesity, inflammation, and hormone dependent malignancies of the endometrium, prostate and breast. This article will review how fundamental knowledge of these enzymes can be exploited in the development of isoform specific HSD inhibitors from both protein superfamilies. Article from the Special issue on Targeted Inhibitors.
羟甾体脱氢酶(HSDs)是一类重要的 NAD(P)(H) 依赖性甾体激素氧化还原酶,参与激素作用的受体前调节。这是通过 HSD 成对工作来实现的,它们可以将酮甾体与羟甾体相互转化,从而改变核受体的配体效力。HSDs 属于两种蛋白质超家族,即醛酮还原酶和短链脱氢酶/还原酶。在人类中,许多重要的酶已经得到了彻底的表征,包括它们的三维结构的阐明。由于这些酶在甾体激素作用中起着基础性作用,因此它们可以被认为是各种甾体驱动疾病的药物靶点,例如代谢综合征和肥胖症、炎症以及子宫内膜、前列腺和乳腺癌的激素依赖性恶性肿瘤。本文将综述如何利用这些酶的基础知识,从两种蛋白质超家族中开发出同工型特异性 HSD 抑制剂。本文选自靶向抑制剂特刊。